Literature DB >> 20535514

Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report.

F Rinaldi1, M Calabrese, D Seppi, M Puthenparampil, P Perini, P Gallo.   

Abstract

Natalizumab has been demonstrated to be highly effective in reducing measures of disease activity, such as clinical relapse rate, and gadolinium (Gd)-enhancing and new or enlarging T2 lesions appearance in patients with relapsing remitting multiple sclerosis (RRMS). Up to date, no data on the effect of natalizumab on cortical pathology have been published. We studied the efficacy of natalizumab in preventing the accumulation of new cortical lesions (CL) in 35 RRMS patients treated for 1 year. While confirming the high impact of natalizumab in reducing the relapse rate (>90%, 85% relapse-free patients) and white matter (WM) pathology (80% patients free from new T2 WM lesions, 97% patients free from new T1 Gd-enhancing lesions), we found that this monoclonal antibody was highly effective in reducing the appearance of new CL (86% patients free from new CL). Our findings indicate a relevant activity of natalizumab against cortical inflammation in RRMS.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 20535514     DOI： 10.1007/s10072-010-0346-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


  21 in total

1.  Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

Authors:  T A Yednock; C Cannon; L C Fritz; F Sanchez-Madrid; L Steinman; N Karin
Journal:  Nature       Date:  1992-03-05       Impact factor: 49.962

2.  Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology.

Authors:  Jeroen J G Geurts; Lars Bö; Petra J W Pouwels; Jonas A Castelijns; Chris H Polman; Frederik Barkhof
Journal:  AJNR Am J Neuroradiol       Date:  2005-03       Impact factor: 3.825

3.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.

Authors:  J W Peterson; L Bö; S Mörk; A Chang; B D Trapp
Journal:  Ann Neurol       Date:  2001-09       Impact factor: 10.422

4.  A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.

Authors:  Massimiliano Calabrese; Maria A Rocca; Matteo Atzori; Irene Mattisi; Alice Favaretto; Paola Perini; Paolo Gallo; Massimo Filippi
Journal:  Ann Neurol       Date:  2010-03       Impact factor: 10.422

5.  Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.

Authors:  N Putzki; K Kollia; S Woods; E Igwe; H C Diener; V Limmroth
Journal:  Eur J Neurol       Date:  2009-03       Impact factor: 6.089

6.  Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis.

Authors:  Massimiliano Calabrese; Nicola De Stefano; Matteo Atzori; Valentina Bernardi; Irene Mattisi; Luigi Barachino; Aldo Morra; Luciano Rinaldi; Chiara Romualdi; Paola Perini; Leontino Battistin; Paolo Gallo
Journal:  Arch Neurol       Date:  2007-10

7.  Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.

Authors:  Norman Putzki; Ozgür Yaldizli; Robert Bühler; Guido Schwegler; Daniela Curtius; Barbara Tettenborn
Journal:  Eur Neurol       Date:  2010-01-16       Impact factor: 1.710

8.  Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.

Authors:  Eva Havrdova; Steven Galetta; Michael Hutchinson; Dusan Stefoski; David Bates; Chris H Polman; Paul W O'Connor; Gavin Giovannoni; J Theodore Phillips; Fred D Lublin; Amy Pace; Richard Kim; Robert Hyde
Journal:  Lancet Neurol       Date:  2009-02-07       Impact factor: 44.182

9.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Authors:  Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

10.  Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration.

Authors:  L Bø; C A Vedeler; H Nyland; B D Trapp; S J Mørk
Journal:  Mult Scler       Date:  2003-08       Impact factor: 6.312
View more
  3 in total

1.  Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.

Authors:  Pietro Iaffaldano; Rosa Gemma Viterbo; Damiano Paolicelli; Guglielmo Lucchese; Emilio Portaccio; Benedetta Goretti; Vita Direnzo; Mariangela D'Onghia; Stefano Zoccolella; Maria Pia Amato; Maria Trojano
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

2.  Gray Matter Pathology in MS: Neuroimaging and Clinical Correlations.

Authors:  Justin Morris Honce
Journal:  Mult Scler Int       Date:  2013-06-25

3.  Early treatment with anti-VLA-4 mAb can prevent the infiltration and/or development of pathogenic CD11b+CD4+ T cells in the CNS during progressive EAE.

Authors:  John E Mindur; Naoko Ito; Suhayl Dhib-Jalbut; Kouichi Ito
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.